<DOC>
	<DOCNO>NCT00892437</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy regimen contain cobicistat-boosted atazanavir ( ATV+COBI ) plus emtricitabine/tenofovir disoproxil fumarate ( Truvada® ; FTC/TDF ) versus ritonavir-boosted atazanavir ( ATV+RTV ) plus FTC/TDF HIV-1 infect , antiretroviral treatment-naive adult . Participants randomize 2:1 ratio . Randomization stratify HIV-1 RNA level ( ≤ 100,000 copies/mL &gt; 100,000 copies/mL ) screening . After Week 48 , participant continue take blind study drug attend visit every 12 week treatment assignment unblinded , point participant return unblinding visit give option participate open-label rollover extension receive ATV+COBI+FTC/TDF COBI tablets become commercially available , Gilead Sciences elect terminate study .</brief_summary>
	<brief_title>Safety Efficacy Cobicistat-boosted Atazanavir Compared Ritonavir-boosted Atazanavir Combination With Emtricitabine/Tenofovir Disoproxil Fumarate HIV-1 Infected , Antiretroviral Treatment-Naive Adults</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>Ability understand sign write informed consent form Plasma HIV1 RNA level ≥ 5,000 copies/mL No prior use approved experimental antiHIV drug Normal ECG ( abnormal , determined investigator clinically significant ) Adequate renal function ( estimate glomerular filtration rate ≥ 80 mL/min accord CockcroftGault formula ) Hepatic transaminases ≤ 2.5 × upper limit normal Total bilirubin ≤ 1.5 mg/dL , normal direct bilirubin Adequate hematologic function ( absolute neutrophil count ≥ 1000/mm^3 ; platelet ≥ 50,000/mm^3 ; hemoglobin ≥ 8.5 g/dL ) Cluster differentiation 4 ( CD4 ) cell count &gt; 50 cells/µL Serum amylase ≤ 1.5 × ULN ( subject serum amylase &gt; 1.5 × ULN remain eligible serum lipase ≤ 1.5 × ULN ) Normal thyroidstimulating hormone Negative serum pregnancy test ( female childbearing potential ) Males females childbearing potential must agree utilize highly effective contraception method screen throughout duration study treatment 30 day follow last dose study drug Age ≥ 18 year Life expectancy ≥ 1 year New AIDSdefining condition diagnose within 30 day prior screen Documented drug resistance nucleoside nucleotide reverse transcriptase inhibitor ( NRTIs ) , nonnucleoside reverse transcriptase inhibitor ( NNRTIs ) , primary PI resistance mutation ( ) Hepatitis B surface antigen positive Hepatitis C antibody positive Participants experience cirrhosis Participants experience ascites Participants experience encephalopathy Females breastfeed Positive serum pregnancy test ( female childbearing potential ) Vaccinated within 90 day study dose History family history Long QT Syndrome family history sudden cardiac death unexplained death otherwise healthy individual age 30 year Presence history cardiovascular disease , cardiomyopathy , and/or cardiac conduction abnormality Prolonged QTcF ( QT interval correct heart rate use Fridericia 's formula ) interval screening ( eg , prolongation QTcF interval great 450 msec male great 470 msec female ) PR interval great equal 200 msec less equal 120 msec ECG screen QRS great equal 120 msec ECG screening Implanted defibrillator pacemaker Subjects receive ongoing therapy disallow medication Current alcohol substance use judge potentially interfere subject study compliance History ongoing malignancy ( include untreated carcinoma insitu ) cutaneous Kaposi 's sarcoma , basal cell carcinoma , resect , noninvasive cutaneous squamous carcinoma Active , serious infection ( HIV1 infection ) require parenteral antibiotic antifungal therapy within 30 day prior baseline Participation clinical trial without prior approval Medications contraindicate use ATV , RTV , FTC , TDF Any known allergy excipients ATV capsule , RTV capsule , COBI tablets FTC/TDF tablet Any clinical condition prior therapy would make subject unsuitable study unable comply dosing requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Antiretroviral Treatment-Naive</keyword>
</DOC>